Project Grant R01AI190348
Award Date
5/13/25
Completion Date
4/30/30
Dollars Obligated
$781K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $657,506 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University. The award, effective August 6, 2024 through July 31, 2025, will fund research to develop a novel subunit vaccine for pertussis that elicits mucosal immunity and prevents nasal colonization by the Bordetella pertussis pathogen. Key activities include testing an intranasal booster vaccine containing...
The University of Georgia Research Foundation, Inc. was awarded a $212,265 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). This grant, titled "Maternal Vaccination Impacts on Neonatal Susceptibility and Response to Bordetella Pertussis," aims to study the mechanisms by which maternal vaccination with acellular pertussis (AP) and whole-cell pertussis (WP) vaccines can confer...
This federal Project Grant award in the amount of $837,644 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to develop novel vaccine candidates targeting the poly-β-(1,6)-N-acetylglucosamine (PNAG) virulence factor, which is present on the surface of many non-viral pathogens. The research team will synthesize a comprehensive library of PNAG glycans with systematically...
This $749,192 federal Project Grant award was made by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will fund research to compare the protective efficacy and host immune responses of different BCG vaccine sub-strains in animal models and correlate these findings with responses in BCG-vaccinated humans. The goal is to better understand the molecular basis for differences in vaccine-induced...
The federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,653,244.00 to The Regents of the University of California, Berkeley (UC Berkeley) to advance the development of improved vaccine adjuvants. The award aims to engineer microbial production of the adjuvant QS-21 and related analogs, as well as study their mechanisms of action through systems immunology...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $207,262 Project Grant (R21AI185820) to The Washington University in St. Louis to develop an mRNA vaccine against Bourbon virus, an emerging tick-borne RNA virus that can infect and cause disease in humans. The primary objective is to evaluate the efficacy of the mRNA vaccine in a mouse model and determine its mechanism of action. A secondary...
This $288,360 federal Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a novel vaccine candidate against multi-drug resistant Acinetobacter baumannii (MDR-AB). The Phase I project focuses on: (1) identifying and characterizing key immunogenic components of MDR-AB to induce protective immunity, (2) developing a prototype vaccine formulation, and (3) conducting...
The federal Project Grant award in the amount of $859,597.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel HIV vaccine candidate. The key objective is to elicit broadly neutralizing antibody responses against the HIV-1 fusion peptide epitope using immunogens based on AB toxin B subunits, such as cholera toxin B (CTB). The award supports a multi-year research...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $270,176 to Oncosting, LLC to develop improved versions of the Bacillus Calmette-Guerin (BCG) vaccine for tuberculosis (TB). Specifically, Oncosting is engineering recombinant BCG strains, OS-101 and OS-151, to overexpress a potent STING agonist with the goal of enhancing the vaccine's protective efficacy and...
This $1,162,224 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to optimize and evaluate the efficacy of oral administration of the BCG vaccine against tuberculosis (TB). The key objectives are: 1) Optimize an oral BCG vaccine regimen, 2) Compare the efficacy of oral BCG to current intravenous and intradermal BCG vaccination approaches using advanced immunological and...